Survival and homing of ex vivo expanded donor derived dendritic cells after allogeneic BMT

Schimmelpfennig, Christoph; Schulz, Stephan; Arber, Caroline; Baker, Jeanette; Tarner, Ingo H.; McBride, Jacqueline; Fathman, C. Garrison; Contag, C.H.; Negrin, Robert S.

doi:10.1186/1475-2867-4-s1-s45

Cited by 3 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, the effective tracking of DCs to the lymph nodes of the patient using a noninvasive imaging method is essential for DC‐based therapy. Thus far, several noninvasive imaging studies on the tracking of DC have been reported, including the use of gamma‐radiation‐emitting radionuclides, such as indium‐111 oxinate (planar gamma scintigraphy),35, 36 fluorine‐18 (PET),37 luciferase or green fluorescent protein (bioluminescence imaging),38 and iron oxide magnetic nanoparticles (MRI) 36, 39, 40…”

mentioning

confidence: 99%

Biocompatible Polymer‐Nanoparticle‐Based Bimodal Imaging Contrast Agents for the Labeling and Tracking of Dendritic Cells

Lim¹,

Noh²,

Han³

et al. 2008

Small

100

View full text Add to dashboard Cite

What a contrast! Agents for both magnetic resonance imaging (MRI) and near‐infrared (NIR) fluorescence imaging are synthesized by encapsulating iron oxide nanoparticles and indocyanine green in a poly(lactide‐co‐glycolide) matrix. The migration of dendritic cells (DCs) via lymphatic drainage is monitored by real‐time NIR fluorescence imaging, and the tracking of DCs into lymph nodes is achieved through noninvasive MRI (see picture).

show abstract

mentioning

confidence: 99%

Biocompatible Polymer‐Nanoparticle‐Based Bimodal Imaging Contrast Agents for the Labeling and Tracking of Dendritic Cells

Lim¹,

Noh²,

Han³

et al. 2008

Small

100

View full text Add to dashboard Cite

show abstract

“…[ 314 ] Another study has shown the trafficking pattern of ex vivo expanded DC, transduced to express luciferase, in mice after allogeneic bone marrow transplantation by BL imaging. [ 347 ] Additionally, it was shown that BLI can be used for monitoring the trafficking of Fluc‐transduced DC after Imiquimod, TLR‐7 agonist, a treatment that enhances the DC survival, while priming tumor‐specific T cells. [ 348 ] These studies provide validation that BLI imaging is potentially a powerful and quantitative tool for the assessment of immunotherapies in melanoma animal studies.…”

Section: Preclinical Studies Of Emerging Therapies: Current Challengesmentioning

confidence: 99%

Nanomedicines as Multifunctional Modulators of Melanoma Immune Microenvironment

Carreira

Acúrcio

Matos

et al. 2020

Advanced Therapeutics

View full text Add to dashboard Cite

Melanoma is the most destructive and deadly among skin cancers. Patients presenting the most disseminated form of this disease have very low survival rates (≈15%) and highly restricted therapeutic alternatives. In recent years, the area of cancer immunotherapy has witnessed remarkable developments in the management of many cancers, including melanoma. In fact, immunotherapy unveiled as a feasible therapeutic alternative for late‐stage melanoma patients, specifically using immune checkpoint therapies. However, despite the exciting outcomes, only a small percentage of patients respond to these therapies, and severe immune‐related adverse reactions have been often reported. As such, most of preclinical and clinical studies currently explore melanoma tumor biology and immunology to guide the development of combinational immunotherapies aiming at relevant clinical efficacy and minimal toxicity. Herein, the current knowledge on melanoma biology and immunology is discussed, focusing on nanotechnology as a crucial strategy for the development of combinatorial approaches able to specifically modulate the function of key players responsible for melanoma evolution and evasion of host immune‐mediated attacks. Finally, the major challenges toward the clinical implementation of these emergent targeted nanomedicines for immunotherapy are further discussed, with particular focus on melanoma genomics, predictive biomarkers, clinical trial design, and clinical regulation of nanomedicines.

show abstract

“…Intrinsic labeling of immunocompetent cells by optical imaging reporter genes and noninvasive imaging of mice has been extensively reported 94–97. Edinger et al 96 labeled effector NK cells and monitored their homing to sites of tumor growth followed by tumor eradication.…”

Section: Optical Imagingmentioning

confidence: 99%

Molecular imaging of cell-based cancer immunotherapy

et al. 2011

View full text Add to dashboard Cite

Cell-based cancer immunotherapy represents a new and powerful weapon in the arsenal of anticancer treatments. Non-invasive monitoring of the disposition, migration and destination of therapeutic cells will facilitate the development of cell based therapy. The therapeutic cells can be modified intrinsically by a reporter gene or labeled extrinsically by introducing imaging probes into the cells or on the cell surface before transplant. Various advanced non-invasive molecular imaging techniques are playing important roles in optimizing cellular therapy by tracking cells and monitoring the therapeutic effects of transplanted cells in vivo. This review will summarize the application of multiple molecular imaging modalities in cell-based cancer immunotherapy.

show abstract

Survival and homing of ex vivo expanded donor derived dendritic cells after allogeneic BMT

Cited by 3 publications

References 0 publications

Biocompatible Polymer‐Nanoparticle‐Based Bimodal Imaging Contrast Agents for the Labeling and Tracking of Dendritic Cells

Biocompatible Polymer‐Nanoparticle‐Based Bimodal Imaging Contrast Agents for the Labeling and Tracking of Dendritic Cells

Nanomedicines as Multifunctional Modulators of Melanoma Immune Microenvironment

Molecular imaging of cell-based cancer immunotherapy

Contact Info

Product

Resources

About